Literature DB >> 17028770

Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy.

Florentia Peintinger1, Henry M Kuerer, Keith Anderson, Judy C Boughey, Funda Meric-Bernstam, S Eva Singletary, Kelly K Hunt, Gary J Whitman, Tanya Stephens, Aman U Buzdar, Marjorie C Green, W Fraser Symmans.   

Abstract

BACKGROUND: Residual tumor size after neoadjuvant chemotherapy is an important consideration in surgical planning. We examined the accuracy of the combination of mammography and sonography in predicting pathologic residual tumor size.
METHODS: Tumor size was evaluated by physical examination, mammography, and sonography at diagnosis and before surgery in 162 breast cancer patients who received neoadjuvant chemotherapy. Agreement between the predicted and the pathologic responses and the predicted and the pathologic tumor sizes was calculated. The effect of invasive lobular carcinoma, high nuclear grade, hormone receptor positivity, and the presence of an extensive intraductal component on the accuracy of mammography and sonography in predicting pathologic residual tumor size was analyzed.
RESULTS: Forty-two patients (25.9%) had a pathologic complete response (pCR). Overall agreement between predicted and pathologic responses was 53% for physical examination, 67% for mammography plus sonography, and 63% for physical examination plus mammography and sonography. The sensitivity of mammography and sonography in predicting pCR was 78.6%, and the specificity was 92.5%; the accuracy was 88.9%. Residual tumor size determined by mammography and sonography correlated with pathologic residual tumor size (r = .662); pathologic tumor size was within .5 cm of predicted in 69.1% of patients. Multivariate analysis showed that pathologic residual tumor size was underestimated for lobular carcinoma and overestimated for poorly differentiated tumors.
CONCLUSIONS: The combination of mammography and sonography has a high accuracy in predicting pCR after neoadjuvant chemotherapy. Agreement of residual tumor size in mammography and sonography with pathologic residual tumor size was moderate.

Entities:  

Mesh:

Year:  2006        PMID: 17028770     DOI: 10.1245/s10434-006-9086-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy.

Authors:  H J Shin; H H Kim; J H Ahn; S-B Kim; K H Jung; G Gong; B H Son; S H Ahn
Journal:  Br J Radiol       Date:  2010-11-16       Impact factor: 3.039

2.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

3.  Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

Authors:  R F D van la Parra; A B Tadros; C M Checka; G M Rauch; A Lucci; B D Smith; S Krishnamurthy; V Valero; W T Yang; H M Kuerer
Journal:  Br J Surg       Date:  2018-02-21       Impact factor: 6.939

4.  A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.

Authors:  Henry M Kuerer; Gaiane M Rauch; Savitri Krishnamurthy; Beatriz E Adrada; Abigail S Caudle; Sarah M DeSnyder; Dalliah M Black; Lumarie Santiago; Brian P Hobbs; Anthony Lucci; Michael Gilcrease; Rosa F Hwang; Rosalind P Candelaria; Mariana Chavez-MacGregor; Benjamin D Smith; Elsa Arribas; Tanya Moseley; Mediget Teshome; Makesha V Miggins; Vicente Valero; Kelly K Hunt; Wei T Yang
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

Review 5.  Neoadjuvant therapy in the treatment of breast cancer.

Authors:  Mediget Teshome; Kelly K Hunt
Journal:  Surg Oncol Clin N Am       Date:  2014-04-24       Impact factor: 3.495

6.  Strain wave elastography in response assessment to neo-adjuvant chemotherapy in patients with locally advanced breast cancer.

Authors:  Amit Katyan; Mahesh Kumar Mittal; Chinta Mani; Ashish Kumar Mandal
Journal:  Br J Radiol       Date:  2019-05-16       Impact factor: 3.039

7.  A Novel Marker, Based on Ultrasound Tomography, for Monitoring Early Response to Neoadjuvant Chemotherapy.

Authors:  Neb Duric; Peter Littrup; Mark Sak; Cuiping Li; Di Chen; Olivier Roy; Lisa Bey-Knight; Rachel Brem
Journal:  J Breast Imaging       Date:  2020-10-27

Review 8.  Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

Authors:  Fanny Le Du; Bedrich L Eckhardt; Bora Lim; Jennifer K Litton; Stacy Moulder; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Naoto T Ueno
Journal:  Oncotarget       Date:  2015-05-30

9.  Role of scintimammography in assessing the response of neoadjuvant chemotherapy in locally advanced breast cancer.

Authors:  Romeeta Trehan; Rajeev K Seam; Manoj K Gupta; Ashwani Sood; Kislay Dimri; Rohit Mahajan
Journal:  World J Nucl Med       Date:  2014-09

10.  The role of mammographic calcification in the neoadjuvant therapy of breast cancer imaging evaluation.

Authors:  Jun-jie Li; Canming Chen; Yajia Gu; Genhong Di; Jiong Wu; Guangyu Liu; ZhiMin Shao
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.